Transtorno de estresse pós-traumático: critérios diagnósticos Posttraumatic stress disorder: diagnostic criteria

Este artigo revisa aspectos da definição da síndrome clínica do transtorno de estresse pós-traumático (TEPT). São apresentados os critérios diagnósticos empregados no DSM-IV e CID-10. Define-se a reação aguda ao estresse (RAE) e contrasta-se a mesma com os critérios que definem o TEPT, salientando-se a importância da expressão parcial dos sintomas de TEPT em vítimas de trauma. Estudos sistemáticos na população de pacientes são caracterizados como uma necessidade a ser endereçada em saúde pública, com vistas ao estabelecimento de protocolos adequados para o diagnóstico e tratamento dessa síndrome clínica.<br>This article reviews aspects of the clinical characterization of the Postttraumatic Stress Disorder (PTSD). The disgnostic criteria used in DSM-IV and ICD-10 are presented. The Acute Reaction to Stress is defined and contrasted to the operational criteria which define the PTSD. The importance of the partial expression of the PTSD syndrome in victims of trauma is highlighted. Systematic studies within this patient population is characterized as a unmet need in public health. Addressing such a need is a major step towards the proper diagnosis and treatment of this clinical syndrome

Comorbidade no transtorno de estresse pós-traumático: regra ou exceção? Comorbidities in posttraumatic stress disorder: rule or excemption?

O transtorno de estresse pós-traumático (TEPT) com frequência ocorre conjuntamente com outros transtornos psiquiátricos. Este artigo revisa o TEPT e comorbidades, tais como: transtornos de ansiedade, uso de substâncias, transtorno de humor, tentativas de suicídio, transtorno dissociativo e transtorno somatoforme.<br>Posttraumatic stress disorder (PTSD) commonly occurs in conjunction with other psychiatric disorders. The present article reviews PTSD and its comorbidities such as anxiety disorders, substance abuse, mood disorders, suicide attempts, dissociative disorder and somatoform disorder

Death to the bad buys: Targeting cancer via Apo2L/TRAIL

The original publication can be found at www.springerlink.comAll higher organisms consist of an ordered society of individual cells that must communicate to maintain and regulate their functions. This is achieved through a complex but highly regulated network of hormones, chemical mediators, chemokines and other cytokines, acting as ligands for intra or extra-cellular receptors. Ligands and receptors of the tumor necrosis factor (TNF) superfamilies are examples of signal transducers, whose integrated actions influence the development, homeostasis and adaptive responses of many cells and tissue types. Apo2L/TRAIL is one of several members of the tumour necrosis factor superfamily that induce apoptosis through the engagement of death receptors. Apo2L/TRAIL interacts with an unusually complex receptor system, which in humans comprises two death receptors and three decoy receptors. This molecule has received considerable attention recently because of the finding that many cancer cell types are sensitive to Apo2L/TRAIL-induced apoptosis, while most normal cells appear to be resistant to this action of Apo2L/TRAIL. In this review, we specifically emphasise on the actions of Apo2L/TRAIL with respect to its apoptotic signaling pathways and summarise what is known about its physiological role. The potential therapeutic usefulness of Apo2L/TRAIL, especially in combination with chemotherapeutic agents, is also discussed in some detail.S. Bouralexis, D. M. Findlay and A. Evdokio